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EDITORIALCirculating Tumor DNA Testing for Liver Cancerirculating tumor DNA (ctDNA) analysis represents aCpotential paradigm shift in personalized medicine.
Unlike tissue biopsy, it constitutes a minimally invasive
approach that allows for diagnostic, predictive, and prog-
nostic marker detection, early and serial assessment of
metastatic disease, therapy monitoring, and determination
of clonal evolution. Because ctDNA reﬂects genetic and
epigenetic alterations from primary cancers, it may be used
for the surrogate analysis of cancer genomes via liquid bi-
opsy, especially in those tumors for which biopsy specimens
are difﬁcult to obtain or unobtainable. Several studies have
supported the potential utility of ctDNA as cancer bio-
markers. Both the levels of ctDNA in the plasma or serum of
cancer patients and cancer-speciﬁc genetic and epigenetic
changes have been detected in ctDNA and have demon-
strated potential diagnostic, prognostic, and predictive
value.1
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer deaths worldwide.2,3 Currently, diagnosis is
based on imaging techniques and/or biopsy. Because the
disease is frequently diagnosed at late stages, prognosis is
poor for HCC patients, with a 5-year survival rate of only
approximately 11%.4 With the advent of large-scale
genomic technologies, the complex mutation landscape of
HCC has been largely deﬁned5,6 and has helped improve the
treatment options for HCC patients. For instance, the mul-
tikinase inhibitor sorafenib has been shown to increase
survival in patients with advanced HCC.7,8 HRAS/NRAS
mutation analysis of ctDNA has been applied in a phase 2
clinical trial to assess response to a mitogen-activated pro-
tein kinase kinase (MEK) inhibition.4 Until now, however, a
comprehensive characterization of ctDNA on HCC patients
has not been conducted.
To evaluate the usefulness of ctDNA for the character-
ization of genomic alterations in HCCs, Ono et al9 per-
formed whole-genome sequencing on 46 HCC samples and
matched normal lymphocytes from patients who under-
went hepatectomy or liver transplantation and for whom
preoperative and postoperative serial serum samples were
available. Somatic alterations were detected in all 46
samples. For each tumor, the authors selected three so-
matic rearrangements and designed primers spanning their
breakpoints for serum ctDNA polymerase chain reaction
testing. They detected ctDNA in the preoperative serum of
7 of the 46 patients. In these patients, serum ctDNA posi-
tivity correlated with larger tumor size and higher ɑ-feto-
protein (AFP) and des-g-carboxy prothrombin (DCP)
levels. The cumulative incidence of recurrence and extra-
hepatic metastasis within 2 years after hepatectomy were
also found to be remarkably worse in ctDNA-positive pa-
tients than in the ctDNA-negative group. Further, ctDNA
was found to be an independent predictor of microscopicCellular and Molecular Gastroenterology and Hepatology 2015;1:458–4vascular invasion of the portal vein, although no statisti-
cally signiﬁcant difference in the cumulative survival rate
was observed between ctDNA-positive and ctDNA-negative
patients.
Ono et al9 also quantiﬁed ctDNA by real-time polymerase
chain reaction in serially sampled serum before and after
surgery from ctDNA-positive patients and demonstrated
that the serum ctDNA levels were increased with disease
progression and reﬂected the response to treatments. Cell-
free DNA was increased after a transcatheter arterial che-
moembolization (TACE) procedure, with the highest level
being detected 4 days after the procedure. In addition, the
authors performed exome sequencing on the primary tu-
mor, and they paired plasma ctDNA in one patient with
HCC/cholangiocarcinoma and found that 83% of mutations
detected in the primary tumor could also be identiﬁed in the
plasma ctDNA. The remaining discrepancy is likely
explained by the low sequencing depth, which provides
insufﬁcient sensitivity for the detection of low-frequency
variants or tumor heterogeneity.
These data have important implications. First, it is
apparent that ctDNA levels reﬂect the cancer progression
and therapy effects on HCC and that the TACE procedure is
capable of enriching ctDNA in cell-free DNA in blood. Sec-
ond, these data demonstrate the potential utility of ctDNA as
a biomarker for individualized management of hepatocel-
lular carcinoma. With further validation, the determination
of HCC genome proﬁles through ctDNA analysis may help
guide individualized therapy selection and monitoring
without requiring percutaneous biopsies.
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